VC-backed Guardant Health goes public
Redwood City, California-based Guardant Health, a liquid biopsy company, has raised $237.5 million for its IPO after pricing its 12.5 million shares at $19 per share. The stock began trading October 4, 2018 on the NASDAQ under the ticker symbol "GH." J.P. Morgan Securities LLC and BofA Merrill Lynch are the lead underwriters. Guardant Health's pre-IPO backers included SoftBank Vision Fund, Sequoia Capital, Khosla Ventures and Lightspeed Venture Partners.
4 October 2018•3 mins read
